Article
Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
2022-12-20
Abstract excerpt
<h4>Background: </h4> Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in diabetic cardiomyopathy remains unclear. We explored the potential functions and mechanisms of finerenone in diabetic cardiomyopathy. Methods After Sprague‐Dawley rats were indu...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ae32d1c4-2a29-5a36-9b14-20930a4263ab
- DOI
- 10.21203/rs.3.rs-2372964/v1
